The regulatory risk is real and worth a candid conversation with legal counsel
Heres what we are going to look at: When D64.9 is appropriate and when its not A documentation checklist for cleaner claims Common anemia ICD-10 codes in a quick-reference table Sequencing rules for neoplasm and therapy-related anemia Code-by-scenario breakdowns for iron deficiency, CKD, chronic disease, chemotherapy, and more TLDR D64.9 covers anemia, unspecified
Sourcing Options and Caveats Given the 2023 FDA ruling, here is the honest landscape: Compounding pharmacies: Most U.S
Enzymatic Sensitivity Experiments: Analysing activation and inhibition patterns across multiple pathways
They can only be used in a safe, controlled laboratory
Until then, buying vials of dry powder, reconstituting it in sterile water, and injecting the cocktail with online-purchased needles will not provide proof of anything